SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 238 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,598,572 | +88.5% | 95,682 | +78.0% | 0.01% | +125.0% |
Q2 2023 | $6,154,648 | -65.3% | 53,743 | -58.3% | 0.00% | -69.2% |
Q1 2023 | $17,755,261 | +229.4% | 128,820 | +209.6% | 0.01% | +160.0% |
Q4 2022 | $5,390,917 | -69.2% | 41,603 | -73.7% | 0.01% | -61.5% |
Q3 2022 | $17,478,000 | +144.8% | 158,110 | +66.0% | 0.01% | +160.0% |
Q2 2022 | $7,140,000 | +80.1% | 95,266 | +87.7% | 0.01% | +150.0% |
Q1 2022 | $3,964,000 | -46.6% | 50,741 | -38.5% | 0.00% | -50.0% |
Q4 2021 | $7,430,000 | +42.9% | 82,510 | +46.8% | 0.00% | +33.3% |
Q3 2021 | $5,198,000 | -50.9% | 56,197 | -58.8% | 0.00% | -50.0% |
Q2 2021 | $10,597,000 | +50.6% | 136,322 | +44.4% | 0.01% | +20.0% |
Q1 2021 | $7,035,000 | -72.5% | 94,386 | -37.1% | 0.01% | -66.7% |
Q4 2020 | $25,569,000 | +11.1% | 149,971 | -8.5% | 0.02% | 0.0% |
Q3 2020 | $23,024,000 | -32.3% | 163,949 | -22.7% | 0.02% | -44.4% |
Q2 2020 | $34,004,000 | +56.3% | 212,085 | -4.7% | 0.03% | +35.0% |
Q1 2020 | $21,758,000 | -54.5% | 222,430 | -40.0% | 0.02% | -42.9% |
Q4 2019 | $47,854,000 | +133.1% | 370,843 | +36.1% | 0.04% | +105.9% |
Q3 2019 | $20,527,000 | -82.5% | 272,540 | -64.7% | 0.02% | -82.1% |
Q2 2019 | $117,444,000 | +268.3% | 772,905 | +188.9% | 0.10% | +196.9% |
Q1 2019 | $31,888,000 | +49.8% | 267,525 | +37.2% | 0.03% | +52.4% |
Q4 2018 | $21,286,000 | +0.9% | 195,052 | +49.3% | 0.02% | +10.5% |
Q3 2018 | $21,095,000 | +38.4% | 130,605 | +13.3% | 0.02% | +35.7% |
Q2 2018 | $15,241,000 | +44.2% | 115,311 | -19.2% | 0.01% | +55.6% |
Q1 2018 | $10,573,000 | -10.0% | 142,713 | -32.4% | 0.01% | 0.0% |
Q4 2017 | $11,752,000 | +57.1% | 211,222 | +28.1% | 0.01% | +50.0% |
Q3 2017 | $7,482,000 | +3.6% | 164,951 | -23.0% | 0.01% | 0.0% |
Q2 2017 | $7,225,000 | +107.4% | 214,294 | +82.1% | 0.01% | +50.0% |
Q1 2017 | $3,484,000 | -19.8% | 117,711 | -25.7% | 0.00% | 0.0% |
Q4 2016 | $4,345,000 | -60.4% | 158,435 | -11.3% | 0.00% | -60.0% |
Q3 2016 | $10,965,000 | +378.8% | 178,555 | +48.7% | 0.01% | +400.0% |
Q2 2016 | $2,290,000 | -41.8% | 120,089 | -40.4% | 0.00% | -60.0% |
Q1 2016 | $3,933,000 | -49.6% | 201,524 | -0.5% | 0.01% | -37.5% |
Q4 2015 | $7,811,000 | +104.4% | 202,465 | +70.1% | 0.01% | +100.0% |
Q3 2015 | $3,822,000 | -8.7% | 119,059 | -13.5% | 0.00% | 0.0% |
Q2 2015 | $4,188,000 | +313.4% | 137,601 | +80.4% | 0.00% | +300.0% |
Q1 2015 | $1,013,000 | +96.7% | 76,295 | +114.9% | 0.00% | – |
Q4 2014 | $515,000 | +409.9% | 35,501 | +642.5% | 0.00% | – |
Q3 2014 | $101,000 | -57.9% | 4,781 | -40.6% | 0.00% | – |
Q2 2014 | $240,000 | -32.6% | 8,050 | -45.6% | 0.00% | – |
Q1 2014 | $356,000 | -37.9% | 14,799 | -47.4% | 0.00% | -100.0% |
Q4 2013 | $573,000 | +15.8% | 28,151 | +168.3% | 0.00% | – |
Q3 2013 | $495,000 | +20.1% | 10,494 | -3.1% | 0.00% | – |
Q2 2013 | $412,000 | – | 10,831 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |